Vaccine Contract Manufacturing Market Report 2026

The vaccine contract manufacturing market size has grown strongly in recent years. It will grow from $3.88 billion in 2025 to $4.27 billion in 2026 at a compound annual growth rate (CAGR) of 10%. The growth in the historic period can be attributed to expansion of global immunization programs, increasing complexity of vaccine production processes, reliance on specialized contract manufacturers, growth of public-private vaccine partnerships, establishment of large-scale vaccine facilities.

The vaccine contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $6.46 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to rising demand for rapid vaccine scale-up capabilities, increasing investments in mRNA and next-generation vaccines, expansion of commercial-scale manufacturing, growing focus on regional vaccine self-sufficiency, adoption of advanced bioprocess technologies. Major trends in the forecast period include increasing outsourcing of vaccine production, rising demand for flexible manufacturing capacity, expansion of fill-finish service capabilities, growing focus on regulatory-compliant manufacturing, increasing adoption of single-use bioprocessing systems.

The rising prevalence of infectious diseases worldwide is expected to drive the growth of the vaccine contract manufacturing market. Infectious diseases are disorders caused by pathogenic microorganisms, including bacteria, viruses, fungi, or parasites. During outbreaks of infectious diseases, such as influenza, measles, or emerging viruses, there is an urgent need for vaccines to prevent further spread. Contract manufacturers play a key role by rapidly scaling up production to meet this demand. For example, in October 2024, the World Health Organization, a Switzerland-based international public health organization, reported that approximately 8.2 million people were newly diagnosed with tuberculosis in 2023, up from around 7.5 million in 2022, making tuberculosis the leading infectious disease killer. Therefore, the increasing incidence of infectious diseases is driving growth in the vaccine contract manufacturing market.

Key companies in the vaccine contract manufacturing market are focusing on opening dedicated production sites to maintain and expand their market presence. Establishing a vaccine contract manufacturing site involves setting up a facility specifically for the contractual production of vaccines. For instance, in September 2023, WuXi Vaccines, a China-based contract development and manufacturing organization (CDMO) specializing in vaccine discovery and production, launched its first standalone vaccine CDMO site in Suzhou, China. This expansion enhances the company’s capabilities for both drug substance and drug product manufacturing. WuXi Vaccines now provides a full range of services covering diverse vaccines, including process development, drug product development, and the production of clinical-scale drug substances (DS) and small-to-medium sterile drug products (DP). The new standalone site increases WuXi Vaccines’ capacity to support vaccine development and manufacturing, playing a crucial role in advancing global healthcare solutions.

In October 2024, SK bioscience, a South Korea-based vaccine and biotech company, acquired controlling stakes in IDT Biologika for approximately $244 million. This acquisition aligns with SK bioscience’s growth strategy and aims to consolidate sales to KRW 1 trillion (approximately USD 757.6 million) within the next five years. The company also plans to expand further with the launch of next-generation pneumococcal vaccines, positioning itself for continued financial growth beyond 2028. IDT Biologika is a German-based vaccine contract development and manufacturing organization (CDMO).

Major companies operating in the vaccine contract manufacturing market are Pfizer Inc, Johnson & Johnson, AbbVie Inc., Sanofi, GlaxoSmithKline, Merck KGaA, Moderna, BioNTech, GSK Vaccines, AstraZeneca PLC, Ajinomoto Co. Inc., Lonza Group AG, Catalent Inc., Charles River Laboratories International Inc., Serum Institute of India Pvt. Ltd, Samsung Biologics, WuXi Biologics, Novavax, Sinovac Biotech, Emergent BioSolutions Inc., Bio Farma, Hualan Biological Engineering, BioMARC, Bavarian Nordic A/S, AGC Biologics, IDT Biologika GmbH, Bharat Biotech, Goodwin Biotechnology Inc., Biofabri S.L.

North America was the largest region in the vaccine contract manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the vaccine contract manufacturing market report forecast period. The regions covered in the vaccine contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vaccine contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the vaccine contract manufacturing market by increasing costs of imported bioreactors, filtration systems, sterile packaging materials, and specialized manufacturing equipment used in bulk production and fill-finish operations. North America and Europe are particularly affected due to reliance on imported bioprocessing equipment, while Asia-Pacific faces higher costs for export-oriented manufacturing inputs. These tariffs are raising capital expenditure requirements and impacting contract pricing structures. At the same time, they are encouraging local manufacturing investments, regional capacity expansion, and strengthening domestic vaccine production ecosystems.

The vaccine contract manufacturing market research report is one of a series of new reports that provides vaccine contract manufacturing market statistics, including vaccine contract manufacturing industry global market size, regional shares, competitors with a vaccine contract manufacturing market share, detailed vaccine contract manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the vaccine contract manufacturing industry. This vaccine contract manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Vaccine contract manufacturing refers to an agreement with external producers to manufacture vaccines, handling production, packaging, and labeling according to the specifications and requirements of the contracting company or organization. The key advantage of vaccine contract manufacturing is that it streamlines production, reducing costs and operational challenges.

The primary services in vaccine contract manufacturing include fill-finish and bulk production. Fill-finish involves the final stages of vaccine manufacturing, where finishing includes sterilizing and standardizing vaccine components into containers, and filling involves placing the vaccine into containers and properly sealing them. The vaccines produced include inactivated vaccines, live-attenuated vaccines, RNA (ribonucleic acid) vaccines, subunit vaccines, and toxoid-based vaccines. These vaccines are manufactured through upstream and downstream processes at preclinical, clinical, and commercial scales for human and veterinary end users.

The vaccine contract manufacturing market consists of revenues earned by entities by providing services such as analytical, quality control studies, cell or virus banking, and cold chain services. The market value includes the value of related goods sold by the service provider or included within the service offering. The vaccine contract manufacturing market also includes sales of synthetic vaccines and DNA (deoxyribonucleic acid) vaccines, which are used in providing vaccine contract manufacturing services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.